Strategic Partnership Announced Between AmplifyBio And RNAV8 Bio To Enhance MRNA Therapeutic Development

In a significant move for the biotechnology sector, AmplifyBio and RNAV8 Bio have announced a strategic partnership aimed at enhancing the development of mRNA therapeutics. This collaboration marks a pivotal step towards creating a streamlined process for bringing mRNA-based treatments from concept to clinic more efficiently and effectively. AmplifyBio, known for its comprehensive Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) services, is joining forces with RNAV8 Bio, an innovative startup specializing in mRNA engineering platforms.

The synergy between AmplifyBio's extensive experience in preclinical safety studies, target optimization, and manufacturing scale-up, combined with RNAV8 Bio's expertise in mRNA design and optimization, promises to offer a one-stop solution for mRNA drug developers. This integrated approach is designed to address the challenges currently faced in rapidly prototyping, testing, iterating, and scaling up mRNA therapeutics.

Devan Shah, CEO at RNAV8 Bio, highlighted the obstacles in the current landscape where the development of mRNA therapeutics is often hindered by fragmented infrastructure and limited technological tools. RNAV8 Bio aims to overcome these challenges by leveraging rational design along with machine learning (ML) and artificial intelligence (AI) to engineer mRNA functions with greater predictability. This approach not only enhances the efficiency of developing therapeutic candidates but also improves their chances of success in treating both rare and common diseases.

The partnership is set to integrate RNAV8’s cutting-edge design and optimization capabilities into AmplifyBio’s established preclinical CRO services, process development, analytical development, and manufacturing capabilities. J. Kelly Ganjei, CEO at AmplifyBio, expressed enthusiasm about the collaboration, emphasizing the strategic alignment of both companies’ capabilities to facilitate rapid iterative development and testing of next-generation mRNA therapeutics.

This collaboration is poised to revolutionize the field by providing comprehensive support for mRNA sequence/chemistry engineering, in vitro performance screening, in vivo model data generation, and scalable mRNA production. The combined expertise of AmplifyBio and RNAV8 Bio aims to address the current gaps in the market by offering a cohesive platform for the development of advanced mRNA therapies.

About RNAV8 Bio: RNAV8 Bio stands at the forefront of mRNA technology innovation. With a team comprising experts from leading pharmaceutical companies such as Moderna, Pfizer, and Resilience, RNAV8 Bio employs rational design coupled with ML/AI techniques to engineer mRNA functions more predictably. The company's unique methodology has shown potential to significantly improve mRNA expression levels over existing industry standards, earning it recognition and partnerships within the biotech community.

About AmplifyBio: Launched from Battelle in 2021, AmplifyBio focuses on ensuring that the development and scale-up of advanced modality drugs are aligned with commercial objectives. The company offers a broad range of services from preclinical toxicology testing to GMP manufacturing, underpinned by a commitment to rich characterization, optimization, and data integrity. AmplifyBio’s approach is designed to ensure reproducibility and effective scale-up in the development of advanced therapies.

The partnership between AmplifyBio and RNAV8 Bio represents a significant leap forward in the quest to streamline the development of mRNA therapeutics. By combining their respective strengths, these two companies are setting a new standard for innovation and efficiency in the biotechnology industry.